MARIBAVIR FOR CYTOMEGALOVIRUS INFECTIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A REAL-WORLD, MULTICENTER, COMPARATIVE COHORT STUDY (EBMT 2026) - Mar 14, 2026 - Abstract #B088; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "All patients tolerated maribavir treatment throughout the study period.Nineteen patients received first-line maribavir for post-HSCT CMV infection, while 20 control patients received other first-line regimens (12 predominantly foscarnet; 8 received combination therapy including ganciclovir or letermovir). In real-world, maribavir demonstrated rapid, effective, and safe clearance of CMV viremia in HSCT recipients. The retrospective cohort study demonstrates comparable CMV clearance rates between first-line maribavir and conventional antiviral regimens in HSCT recipients."
Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Transplantation
|
|
Jiaxin Cao1; Lu Wang2; Xueyao Li1; Shunqing Wang3; Aiming Pang4; Liping Dou2; Erlie Jiang4
|